On December 11, QIAGEN closed the acquisition of SABiosciences Corporation, following the expiration of the statutory waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. SABiosciences brings to QIAGEN an unique position in the design and commercialization of more than 100 PCR assay panels that permits high-performance analysis of DNA, RNA, epigenetic, and microRNA targets in biological pathways associated with specific diseases. QIAGEN can now offer the most comprehensive solutions from sample to result: QIAGEN's sample preparation, PCR chemistry, and instrumentation, together with SABiosciences ready-to-use PCR assay panels, controls, and data and pathway analysis tools.


In vitro pharmacology, Genomic service






© 2015 The World of CROs. All rights reserved.